Burning Rock Biotech Limited Sponsored ADR
BNR Healthcare Diagnostics & Research
Burning Rock Biotech Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $77.2 million, up 9.18% from fiscal 2024. In the quarter to June 2026, revenue fell 4.22%, EPS fell 98.4%, free cash flow grew 46.0% and total debt fell 5.02%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow BNR
Burning Rock Biotech Limited Sponsored ADR (BNR) EV/Sales
As of 16 October 2026, Burning Rock Biotech Limited Sponsored ADR (BNR) trades at a EV/Sales of 17.9×. Over the past ten years it has ranged from −0.3× (March 2025) to 648× (February 2021); the current reading is higher than 79% of that period. That is above the Diagnostics & Research industry median of 5.5× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.9× | 23,798.73% |
| FY2024 | 0.0× | (96.06%) |
| FY2023 | 0.2× | (83.21%) |
| FY2022 | 1.2× | (87.56%) |
| FY2021 | 9.6× | (97.44%) |
| FY2020 | 376× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 11.5× | (47.58%) |
| Mar 2026 | 22.0× | 1,063.70% |
| Dec 2025 | 1.9× | 365.83% |
| Sep 2025 | 0.4× | (89.22%) |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MBAI MBody AI Ltd. compare | n/m |
| MYGN Myriad Genetics, Inc. compare | 0.5× |
| MDXH MDxHealth SA compare | 0.8× |
| BDSX Biodesix, Inc. compare | 2.5× |
| XGN Exagen Inc. compare | 2.6× |
| QUCY Quantum Cyber N.V compare | 8.4× |
| BNR Burning Rock Biotech Limited Sponsored ADR | 17.9× |
| MDXHF MedX Health Corp. compare | 29.4× |
| IMDX Insight Molecular Diagnostics Inc. compare | 55.7× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)